PreveCeutical Medical Inc. (PREV.CN)
CAD 0.02
(0.0%)
CAD 0.02
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -955.08 Thousand CAD | 16.76% |
| 2022 | -1.02 Million CAD | -21.84% |
| 2021 | -1.27 Million CAD | 56.77% |
| 2020 | -2.07 Million CAD | 38.04% |
| 2019 | -2.83 Million CAD | 60.65% |
| 2018 | -11.33 Million CAD | -82.91% |
| 2017 | -7.05 Million CAD | -71.23% |
| 2016 | -3.1 Million CAD | -4230.13% |
| 2015 | -62.45 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -139.61 Thousand CAD | 55.43% |
| 2024 Q2 | -273.02 Thousand CAD | -82.62% |
| 2023 Q4 | -350.25 Thousand CAD | -132.44% |
| 2023 Q3 | -150.68 Thousand CAD | 5.87% |
| 2023 Q1 | -292.25 Thousand CAD | -12.05% |
| 2023 FY | - CAD | 12.36% |
| 2023 Q2 | -160.08 Thousand CAD | 45.22% |
| 2022 Q1 | -159.93 Thousand CAD | 44.59% |
| 2022 Q3 | -494.31 Thousand CAD | -186.26% |
| 2022 Q4 | -260.81 Thousand CAD | 47.24% |
| 2022 Q2 | -172.68 Thousand CAD | -7.97% |
| 2022 FY | - CAD | -21.84% |
| 2021 FY | - CAD | 56.77% |
| 2021 Q1 | -375.84 Thousand CAD | 75.58% |
| 2021 Q4 | -288.66 Thousand CAD | -425.94% |
| 2021 Q3 | 88.56 Thousand CAD | 127.95% |
| 2021 Q2 | -316.81 Thousand CAD | 15.71% |
| 2020 Q3 | 422.63 Thousand CAD | 159.42% |
| 2020 FY | - CAD | 38.04% |
| 2020 Q1 | -237.66 Thousand CAD | -1293.71% |
| 2020 Q2 | -711.23 Thousand CAD | -199.26% |
| 2020 Q4 | -1.53 Million CAD | -464.09% |
| 2019 Q3 | -859.74 Thousand CAD | 41.89% |
| 2019 Q2 | -1.47 Million CAD | -46.0% |
| 2019 Q4 | 19.91 Thousand CAD | 102.32% |
| 2019 Q1 | -1.01 Million CAD | 58.45% |
| 2019 FY | - CAD | 60.65% |
| 2018 Q1 | -1.4 Million CAD | 43.71% |
| 2018 FY | - CAD | -82.91% |
| 2018 Q4 | -2.43 Million CAD | 4.32% |
| 2018 Q3 | -2.54 Million CAD | -33.13% |
| 2018 Q2 | -1.91 Million CAD | -36.31% |
| 2017 Q1 | -94.55 Thousand CAD | 20.86% |
| 2017 Q2 | -668.42 Thousand CAD | -606.91% |
| 2017 Q3 | -1.12 Million CAD | -68.31% |
| 2017 FY | - CAD | -71.23% |
| 2017 Q4 | -2.49 Million CAD | -121.84% |
| 2016 Q3 | -106.02 Thousand CAD | -297.5% |
| 2016 Q1 | -32.29 Thousand CAD | -90.42% |
| 2016 Q2 | -26.67 Thousand CAD | 17.41% |
| 2016 FY | - CAD | -4230.13% |
| 2016 Q4 | -119.47 Thousand CAD | -12.69% |
| 2015 Q4 | -16.96 Thousand CAD | -895.36% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | -1704.00 CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -4.98 Million CAD | 80.827% |
| Asep Medical Holdings Inc | -8.13 Million CAD | 88.261% |
| BetterLife Pharma Inc. | -3.19 Million CAD | 70.074% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 87.576% |
| ChitogenX Inc. | -2.69 Million CAD | 64.548% |
| Rapid Dose Therapeutics Corp. | -3.02 Million CAD | 68.424% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 92.465% |
| Entheon Biomedical Corp. | 13.99 Thousand CAD | 6925.47% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 81.547% |
| Glow Lifetech Corp. | -1.26 Million CAD | 24.382% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | -47.316% |
| Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -34.484% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | -198.953% |
| MYND Life Sciences Inc. | -1.82 Million CAD | 47.672% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | 20.562% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 68.617% |
| Telescope Innovations Corp. | -5.49 Million CAD | 82.605% |